Ms. Huster joined Cooper University Health Care in 2020. She has operational oversight of all medical/surgical units.
Prior to joining Cooper, Ms. Huster served in various nursing and leadership roles at Virtua Health System in South Jersey for over 15 fifteen years. She also served in the United States Army/Reserves for 17 years in various clinical roles from medic to licensed practical nurse and finally as a registered nurse.
Dr. Brapoh joined Cooper University Health Care in 2023. She provides strategic oversight for nursing quality, education, professional development, and wound care.
Dr. Mapp joined Cooper University Health Care in 2023. She provides operational oversight for the Women’s and Children’s Institute, including Obstetrics and Gynecology, Pediatrics, Child Life, Neonatal and Pediatric Critical Care, Cleft Palate Clinic, and the Safe Kids Outreach Program as well as Respiratory, Pulmonary Function Testing, and Interventional Pulmonary.
Ms. Gruber joined Cooper in 1989 and has advanced from a staff nurse to her current position of Assistant Vice President, Nursing Operations. She provides operational oversight for Emergency Services, Urgent Care Centers, Inpatient Psychiatry, Cooper Transfer Center, Supplemental Staffing, and Logistics.
Ms. Campbell is the Chief Advanced Practice Provider. Her administrative responsibilities include oversight and standardization of recruitment/retention, professional development and engagement, quality and safety, education and research activities for Advanced Practice Providers (APPs) and Licensed Independent Practitioners (LIPs). This broad oversight includes Nurse Practitioners, Physician Assistants, CRNAs and Psychologists. Ms.
Ms. Floyd started her nursing career in 1981 graduating with a diploma in nursing and immediately transitioned into critical care. Years at the bedside and desire to grow both in skill and knowledge resulted in further pursuit of career goals including a BSN and later a Master of Science in Nursing with an Emphasis in Nursing Education (MSN-Ed) degree.
Dr. Devine is responsible for professional nursing practice across the continuum of care to ensure safety, service, and quality outcomes for Cooper University Health Care's diverse patient population. In addition, she has administrative and operational leadership responsibility for Nursing and Patient Care Services. As SVP/CNE, Dr. Devine continues to advance nursing practice by engaging nurses in re-defining a professional practice model and shared governance structure that are grounded in theoretical tenets which align to organizational mission, vision, and values.
Short Title: Phoenix
To learn if cemiplimab can help to control dMMR colon cancer.
Study Number:
2023-0228
Study Status:
Enrolling
Treatment Agent:
Cemiplimab
National Clinical Trial Identified Number: NCT05961709
Disease:
Study Phase:
II
researchcancer@cooperhealth.edu
Phase II trial of cemiplimab for the non-operative management of localized dMMR colon cancer
Hide from Search:
Off
Physician Name:
Department:
Short Title: Exceptional Responders
This clinical trial studies eliminating surgery and how well radiation therapy after systemic therapy works in treating patients with HER2 positive or triple negative breast cancer when image-guided biopsy shows no residual cancer. Patients then receive standard breast radiotherapy.
Study Number:
2016-0046
Study Status:
Enrolling
Treatment Agent:
Radiation, Surgery
National Clinical Trial Identified Number: NCT02945579
Disease:
Study Phase:
Not applicable
researchcancer@cooperhealth.edu
Multicenter trial for eliminating breast cancer surgery or radiotherapy in exceptional responders to neoadjuvant systemic therapy
Hide from Search:
Off
Physician Name:
Short Title: DIRECT
This phase II trial tests how well an imaging procedure called fludeoxyglucose F-18 (FDG) positron emission tomography/computed tomography (PET/CT) works in predicting response to standard of care chemotherapy prior to surgery in patients with HER2-positive stage IIa-IIIc breast cancer. FDG is a radioactive tracer that is given in a vein before PET/CT imaging and helps to identify areas of active cancer. PET and CT are imaging techniques that make detailed, computerized pictures of areas inside the body. The use of FDG-PET/CT may help doctors better decide if a patient needs more or less treatment before surgery in order to get the best response. This study evaluates whether FDG-PET/CT is useful in predicting a patient's response to standard of care chemotherapy.
Study Number:
EA1211
Study Status:
Enrolling
Treatment Agent:
Chemotherapy
National Clinical Trial Identified Number: NCT05710328
Disease:
Study Phase:
II
researchcancer@cooperhealth.edu
Interim FDG-PET/CT for PreDIcting REsponse of HER2+ Breast Cancer to Neoadjuvant Therapy
Hide from Search:
Off
Physician Name:
Department:
